Van de Werf F
Department of Cardiology, University Hospital Gasthuisberg, Leuven, Belgium.
Z Kardiol. 1993;82 Suppl 2:171-4.
The immediate direct aim of thrombolytic therapy is rapid recanalization of the infarct-related coronary artery. Coronary patency rates observed in the different placebo-controlled and direct comparative trials of thrombolytic agents at different times after the onset of treatment are summarized. It is concluded that 1) for early reperfusion rt-PA is more effective than the other agents, 2) but that at the time of hospital discharge the observed patency rates are very similar for the different fibrinolytic agents and, surprisingly, not different from those obtained with antithrombotic treatment alone (= combined effect of endogenous thrombolysis and antithrombotic treatment!). New approaches to improve early reperfusion rates are discussed.
溶栓治疗的直接近期目标是使梗死相关冠状动脉迅速再通。总结了在不同溶栓药物的安慰剂对照和直接对比试验中,治疗开始后不同时间观察到的冠状动脉通畅率。得出以下结论:1)对于早期再灌注,重组组织型纤溶酶原激活剂(rt-PA)比其他药物更有效;2)但在出院时,不同纤溶药物观察到的通畅率非常相似,令人惊讶的是,与单独抗血栓治疗所获得的通畅率并无差异(=内源性溶栓和抗血栓治疗的联合作用!)。还讨论了提高早期再灌注率的新方法。